2
Mar
2018

Celgene Drops the Ball and a Flurry of VC Deals: Frontpoints

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Madrigal’s Historic First for MASH, IFM’s Hat Trick, & BIO on Election Defense
Startups Challenge Vertex, BMS, Takeda & the Weight Loss Drug Revival Continues
Vertex’s Next Big Thing, Regeneron’s Cell Therapy Play, & Takeda Bets on Protagonist
Sanofi Shells Out for Inhibrx, CG’s Breakout IPO, & a Cure for a Rare Deafness